Carlota Iñiguez Ubiaga , Carlos García Porrúa , José Antonio Pinto Tasende , Lorena Paula Iñiguez Ubiaga , Amalia Sánchez-Andrade Fernandez
{"title":"肝纤维化4评分:用于评估银屑病关节炎患者的非酒精性脂肪性肝病","authors":"Carlota Iñiguez Ubiaga , Carlos García Porrúa , José Antonio Pinto Tasende , Lorena Paula Iñiguez Ubiaga , Amalia Sánchez-Andrade Fernandez","doi":"10.1016/j.reumae.2023.04.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>To describe the prevalence of non-alcoholic fatty liver disease (NAFLD), the association between FIB4 and ultrasound findings, and the clinical characteristics of psoriatic arthritis patients.</p></div><div><h3>Material and methods</h3><p>We carried out an observational cross-sectional study of patients seen in the outpatient clinic from January 1st, 2020, to November 30th, 2020, with psoriatic arthritis.</p></div><div><h3>Results</h3><p>Of the 90 patients studied, the prevalence of NAFLD was 56.67%. FIB4 presents an association with ultrasound findings (p = .030), the absence of enthesitis (p = .036), and longer duration of disease (Rho .213 p = .042). It also presents an association with hypertension (p = .027) and alcohol consumption (p = .021). However, biological treatment can be considered as a protective factor (p = .005). FIB4 acts as a NAFLD predictor with 69.2% sensitivity and 70.4% specificity.</p></div><div><h3>Conclusions</h3><p>The prevalence of NAFLD was higher in our sample than in the standard population. FIB4 index may be useful in screening for silent liver damage in psoriatic arthritis in clinical practice.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Liver fibrosis 4 score: Use in the evaluation of non-alcoholic fatty liver disease in patients with psoriatic arthritis\",\"authors\":\"Carlota Iñiguez Ubiaga , Carlos García Porrúa , José Antonio Pinto Tasende , Lorena Paula Iñiguez Ubiaga , Amalia Sánchez-Andrade Fernandez\",\"doi\":\"10.1016/j.reumae.2023.04.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>To describe the prevalence of non-alcoholic fatty liver disease (NAFLD), the association between FIB4 and ultrasound findings, and the clinical characteristics of psoriatic arthritis patients.</p></div><div><h3>Material and methods</h3><p>We carried out an observational cross-sectional study of patients seen in the outpatient clinic from January 1st, 2020, to November 30th, 2020, with psoriatic arthritis.</p></div><div><h3>Results</h3><p>Of the 90 patients studied, the prevalence of NAFLD was 56.67%. FIB4 presents an association with ultrasound findings (p = .030), the absence of enthesitis (p = .036), and longer duration of disease (Rho .213 p = .042). It also presents an association with hypertension (p = .027) and alcohol consumption (p = .021). However, biological treatment can be considered as a protective factor (p = .005). FIB4 acts as a NAFLD predictor with 69.2% sensitivity and 70.4% specificity.</p></div><div><h3>Conclusions</h3><p>The prevalence of NAFLD was higher in our sample than in the standard population. FIB4 index may be useful in screening for silent liver damage in psoriatic arthritis in clinical practice.</p></div>\",\"PeriodicalId\":94193,\"journal\":{\"name\":\"Reumatologia clinica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reumatologia clinica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S217357432300093X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S217357432300093X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Liver fibrosis 4 score: Use in the evaluation of non-alcoholic fatty liver disease in patients with psoriatic arthritis
Objectives
To describe the prevalence of non-alcoholic fatty liver disease (NAFLD), the association between FIB4 and ultrasound findings, and the clinical characteristics of psoriatic arthritis patients.
Material and methods
We carried out an observational cross-sectional study of patients seen in the outpatient clinic from January 1st, 2020, to November 30th, 2020, with psoriatic arthritis.
Results
Of the 90 patients studied, the prevalence of NAFLD was 56.67%. FIB4 presents an association with ultrasound findings (p = .030), the absence of enthesitis (p = .036), and longer duration of disease (Rho .213 p = .042). It also presents an association with hypertension (p = .027) and alcohol consumption (p = .021). However, biological treatment can be considered as a protective factor (p = .005). FIB4 acts as a NAFLD predictor with 69.2% sensitivity and 70.4% specificity.
Conclusions
The prevalence of NAFLD was higher in our sample than in the standard population. FIB4 index may be useful in screening for silent liver damage in psoriatic arthritis in clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
